Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 4/20 | 0.77 |
| ▸ | GABBR1 | Q9UBS5 | 4/20 | 0.77 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 11/20 | 0.47 |
| ▸ | PIM2 | Q9P1W9 | 5/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.45 |
| ▸ | GALR2 | O43603 | 1/20 | 0.44 |
| ▸ | GALR1 | P47211 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3109197 | 0.87 | GABBR2 (1.00) | GABBR2GABBR1IRAK1GALR2GALR1 | |
| SCHEMBL3123747 | 0.84 | GABBR2 (0.75) | GABBR2GABBR1PDE10APIM1PIM2 | |
| SCHEMBL3112867 | 0.82 | GABBR2 (0.61) | GABBR2GABBR1IRAK1IRAK4 | |
| SCHEMBL3121937 | 0.80 | GABBR2 (0.52) | GABBR2GABBR1PIM1PIM2FLT3 | |
| SCHEMBL3117412 | 0.79 | GABBR2 (0.70) | GABBR2GABBR1IRAK1IRAK4 | |
| SCHEMBL27735613 | 0.77 | GABBR2 (0.56) | GABBR2GABBR1IRAK1IRAK4 | |
| SCHEMBL3122586 | 0.76 | GABBR2 (0.67) | GABBR2GABBR1PDE10AIRAK1IRAK4 | |
| SCHEMBL3122477 | 0.76 | GABBR2 (0.78) | GABBR2GABBR1IRAK1IRAK4 | |
| SCHEMBL3121907 | 0.76 | GABBR2 (1.00) | GABBR2GABBR1PDE10APIM1IRAK1 | |
| SCHEMBL3113855 | 0.75 | ABCG2 (0.55) | GABBR2GABBR1IRAK1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
| CN-101193868-A | Pyrimidine derivatives for the treatment of GABA B mediated nervous system disorders | NOVARTIS AG (CH) | 2008-06-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | DPYD, NUDT1, HPRT1 | GABBR2 1611/4885GABBR1 1499/4885PDE10A 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.